Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGIS5Q)

• Drug Name: pCMPS Drug Info
• Synonyms: para-Chloromercuriphenylsulfonate; p-Chloromercuribenzenesulfonate; pCMBS

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11136
  ChEBI ID: CHEMBL33206
  CAS Number: CAS 554-77-8
  TTD Drug ID: DMGIS5Q

Molecule-Related Drug Atlas

Drug(s) Targeting P2Y purinoceptor 12 (P2RY12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[2]
Prasugrel	DM7MT6E	Acute coronary syndrome	BA41	Approved	[4]
Brilinta	DMBR01X	Acute coronary syndrome	BA41	Approved	[5]
Cangrelor	DM8JRH0	Thrombosis	DB61-GB90	Approved	[6]
INS-50589	DMKZUVC	Cardiovascular disease	BA00-BE2Z	Phase 2	[7]
Elinogrel	DMA4BRV	Myocardial infarction	BA41-BA43	Phase 1	[8]
ARL-67085	DMY5IM2	Thrombosis	DB61-GB90	Phase 1	[9]
adenosine diphosphate	DMFUHKP	N. A.	N. A.	Investigative	[2]
2MeSADP	DMGADQ1	Discovery agent	N.A.	Investigative	[10]
2MeSAMP	DMBO2DC	Discovery agent	N.A.	Investigative	[10]

Drug(s) Affected By Aldo-keto reductase family 1 member B10 (AKR1B10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[11]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[12]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[13]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[14]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[15]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[16]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[17]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[18]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[19]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 12 (P2RY12)	TTZ1DT0	P2Y12_HUMAN	Antagonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member B10 (AKR1B10)	OTOA4HTH	AK1BA_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1773).
• [2] P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22.
• [3] Modulation of activity and inhibitor sensitivity of rabbit aldose reductase-like protein (AKR1B19) by oxidized glutathione and SH-reagents. Chem Biol Interact. 2013 Feb 25;202(1-3):146-52.
• [4] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [5] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328).
• [7] Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56.
• [8] Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.
• [9] Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
• [10] Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9.
• [11] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [12] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [13] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [14] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [15] Identification of approved drugs as potent inhibitors of pregnane X receptor activation with differential receptor interaction profiles. Arch Toxicol. 2018 Apr;92(4):1435-1451.
• [16] Characterization of drug-specific signaling between primary human hepatocytes and immune cells. Toxicol Sci. 2017 Jul 1;158(1):76-89.
• [17] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [18] Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
• [19] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [20] Keratinocyte gene expression profiles discriminate sensitizing and irritating compounds. Toxicol Sci. 2010 Sep;117(1):81-9.